Please login to the form below

Not currently logged in
Email:
Password:

Ipsen appoints executive vice president

Alexandre Lebeaut also set to be chief scientific officer

Alexandre_Lebeaut_IpsenIpsen has appointed Dr Alexandre Lebeaut as its new executive VP, research and development, and chief scientific officer to focus on the firm’s strategy to address unmet medical needs.

Lebeaut joined Ipsen in 2013 as senior VP, chief development officer, global drug development and was appointed interim head of R&D in December 2016.

Prior to joining Ipsen, Lebeaut has held several leadership positions in clinical development and medical affairs with biopharmaceutical companies including Axcan Pharmaceuticals, Sanofi and Novartis.

David Meek, CEO of Ipsen, said: “Dr Lebeaut has consistently demonstrated an unwavering commitment to innovation, collaboration and successful execution of drug development strategies.

“During his four years at Ipsen, Dr Lebeaut has been instrumental in successfully leading our global development programmes.

“He will continue to lead the transformation of Ipsen’s R&D strategy to further build a differentiated and sustainable portfolio to continue to address unmet medical needs in our key areas of expertise.”

18th April 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

the_other_side_of_rheumation_arthritis_thumb.jpg
THE OTHER SIDE OF … RHEUMATOID ARTHRITIS
“I harassed my GP enough to get it caught early”...
The big dilemma in international digital pharma marketing
How to get consistent international marketing while meeting local affiliates’ needs....
Why pharma content marketing campaigns should be agile
Agile pharma content marketing is simply about responding to customer needs, rather than your own whims....

Infographics